Repro Med Systems – Consensus Indicates Potential 80.9% Upside

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Repro Med Systems found using ticker (KRMD) have now 4 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 16 and 9 and has a mean target at 11.25. With the stocks previous close at 6.22 this would imply there is a potential upside of 80.9%. The day 50 moving average is 4.93 while the 200 day moving average is 7.6. The company has a market capitalisation of $278m. Find out more information at: http://www.korumedical.com

The potential market cap would be $502m based on the market concensus.

Repro Med Systems, doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems was founded in 1980 and is headquartered in Chester, New York.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search